Daveen Chopra

Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies, Edwards Lifesciences

Search every verified Daveen Chopra interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Daveen Chopra, corporate vice president of Transcatheter Mitral and Tricuspid Therapies (TMTT) at Edwards Lifesciences, discussed the company’s focus on developing a portfolio of therapies to repair or replace the mitral and tricuspid valves. In a September 2024 podcast interview, Chopra described the tricuspid valve as having been “called the forgotten valve” and noted that treating tricuspid disease can improve patients’ quality of life. He stated that only 13 out of 100 patients in the U.S. with severe aortic stenosis receive treatment each year, and said many patients with mitral and tricuspid valve disease are not diagnosed or treated. Chopra also commented that the recent approval of transcatheter tricuspid valve replacement provides options for patients who previously had no treatment alternatives. Chopra said the reorganization at Edwards allows the company to deepen its focus on structural heart and take more risks in innovation. He stated that innovation can come from inside or outside the company and that Edwards aims to bring those innovations to market. Chopra noted that current transcatheter valves require 24 hours of sewing per valve and that the company is working to make products easier and more manufacturable. He said Edwards is committed to continuing large pivotal clinical studies and working with regulatory agencies to change the practice of medicine through clinical data. Chopra added that as the sector grows, more patients will receive treatments that were not available to them previously.